Neurotrophic Keratitis Overview
Learn About Neurotrophic Keratitis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Alessandro Lambiase practices in Rome, Italy. Mr. Lambiase is rated as an Elite expert by MediFind in the treatment of Neurotrophic Keratitis. His top areas of expertise are Neurotrophic Keratitis, Giant Papillary Conjunctivitis, Vernal Keratoconjunctivitis, Vitrectomy, and Corneal Transplant.
Marta Sacchetti practices in Rome, Italy. Ms. Sacchetti is rated as an Elite expert by MediFind in the treatment of Neurotrophic Keratitis. Her top areas of expertise are Neurotrophic Keratitis, Allergic Conjunctivitis, Giant Papillary Conjunctivitis, Corneal Transplant, and Awake Craniotomy.
Pratt Ophthalmology Associates Inc
Pedram Hamrah is an Ophthalmologist in Boston, Massachusetts. Dr. Hamrah is rated as an Elite provider by MediFind in the treatment of Neurotrophic Keratitis. His top areas of expertise are Interstitial Keratitis, Neurotrophic Keratitis, Dry Eye Syndrome, Hereditary Keratitis, and Corneal Transplant. Dr. Hamrah is currently accepting new patients.
Summary: This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK). The study plans to enroll 48 patients with Mackie Stage 2 or 3 NK affecting one or both eyes. Eligible subjects will be randomized 1:1:1 into three dosing groups. Each dosing group will follow a drug-placebo allocation (12 act...
Summary: The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via topical application. This is a Phase 1/2, multicenter, double-masked, placebo-controlled study to evaluate the safety, tole...